Pipeline · VNQ-218Active studySynthetic mock data
VNQ-218 — HER3
ADC · Pancreatic, gastric · Phase I
Modality
ADC
Target
HER3
Phase
Phase I
Toxicity flags
4
Mechanism
VNQ-218 is a adc engineered to engage HER3 with the goal of a clinically meaningful response in Pancreatic, gastric. Currently in Phase I; next milestone: Cohort review w/ DSMB.
Dose-escalation cohorts
| Dose | Cohort N | DLTs | Status |
|---|---|---|---|
| 1.6 mg/kg | 3 | 0 | cleared |
| 3.2 mg/kg | 6 | 1 | cleared |
| 4.8 mg/kg | 6 | 2 | halted |
| 6.4 mg/kg | 0 | 0 | open |
Recent toxicity events
4 active| Date | Case | Grade | Term | Resolved |
|---|---|---|---|---|
| 2026-04-22 | E0210-HCC-007 | G3 | Neutropenia | Active |
| 2026-04-18 | E0210-HCC-009 | G3 | ILD / pneumonitis | Active |
Linked studies
Cross-links